British anti-Lewisite
By Domingo Tabangcura, Jr. and G. Patrick Daubert, MD


  1. Wolf, H.W., R, Rubber: A Story of Glory and Greed. 1936, New York: Covici, Friede.
  2. Ord, M. and L. Stocken, A contribution of chemical defence in World War II. Trends Biochem Sci, 2000. 25: p. 253-6.
  3. Peters, R., L. Stocken, and R. Thompson, British anti-Lewisite (BAL). Nature, 1945. 156: p. 616-9.
  4. Subramanian, I., Z. Vanek, and J. Bronstein, Diagnosis and treatment of Wilson's disease. Curr Neurol Neurosci Rep, 2002. 2(4): p. 317-23.
  5. Cumings, J., The copper and iron content of brain and liver in the normal and in hepatolenticular degeneration. Brain, 1948. 71: p. 410-5.
  6. Mandelbrote, B., et al., Studies on copper metabolism in demyelinating diseases of the central nervous system. Brain, 1948. 71: p. 212-28.
  7. Denny-Brown, D. and H. Porter, The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilsonís disease). Proc Am Neurol Assoc, 1951(79-84).
  8. Vilensky, J. and K. Redman, British Anti-Lewisite (Dimercaprol): An Amazing History. Ann Emerg Med, 2003. 41(3): p. 378-83.
  9. Gilman, A., Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed ed, ed. A. Gilman, T. Rall, and A. Nies. 1990, New York, NY: Pergamon Press.
  10. Chisolm, J.J., The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediatr, 1968. 73: p. 1-38.
  11. Tamboline, B., A. Matheson, and S. Zbarsky, Radioactive compounds excreted by rats treated with 35S-labelled BAL: Preliminary studies. Biochem J, 1955. 61: p. 651-7.
  12. Mückter, H.L., B; Reichl, FX, Are we ready to replace dimercaprol (BAL) as an arsenic antidote? Hum Exp Toxicol, 1997. 16(8): p. 460-5.
  13. Micromedex, T., Dimercaprol, in MICROMEDEX(R) Healthcare Series. 2000: Greenwood Village, CO.
  14. Janakiraman, N., et al., Hemolysis during BAL chelation therapy for high blood lead levels in two G6PD deficient children. Clin Pediatr, 1978. 17: p. 485-7.
  15. Kalia, K.F., SJ, Strategies for safe and effective therapeutic measures for chronic arsenic and lead poisoning. J Occup Health, 2005. 47(1): p. 1-21.